Literature DB >> 25061165

Molecular response in CML: where is the bar?

Michele Baccarani1, Simona Soverini1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25061165      PMCID： PMC4110650          DOI： 10.1182/blood-2014-06-578617

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

1.  Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Authors:  David Marin; Amr R Ibrahim; Claire Lucas; Gareth Gerrard; Lihui Wang; Richard M Szydlo; Richard E Clark; Jane F Apperley; Dragana Milojkovic; Marco Bua; Jiri Pavlu; Christos Paliompeis; Alistair Reid; Katayoun Rezvani; John M Goldman; Letizia Foroni
Journal:  J Clin Oncol       Date:  2011-11-07       Impact factor: 44.544

2.  Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.

Authors:  Susan Branford; David T Yeung; Wendy T Parker; Nicola D Roberts; Leanne Purins; Jodi A Braley; Haley K Altamura; Alexandra L Yeoman; Jasmina Georgievski; Bronte A Jamison; Stuart Phillis; Zoe Donaldson; Mary Leong; Linda Fletcher; John F Seymour; Andrew P Grigg; David M Ross; Timothy P Hughes
Journal:  Blood       Date:  2014-05-23       Impact factor: 22.113

3.  Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

Authors:  B Hanfstein; M C Müller; R Hehlmann; P Erben; M Lauseker; A Fabarius; S Schnittger; C Haferlach; G Göhring; U Proetel; H-J Kolb; S W Krause; W-K Hofmann; J Schubert; H Einsele; J Dengler; M Hänel; C Falge; L Kanz; A Neubauer; M Kneba; F Stegelmann; M Pfreundschuh; C F Waller; S Branford; T P Hughes; K Spiekermann; G M Baerlocher; M Pfirrmann; J Hasford; S Saußele; A Hochhaus
Journal:  Leukemia       Date:  2012-03-26       Impact factor: 11.528

4.  Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.

Authors:  B Hanfstein; V Shlyakhto; M Lauseker; R Hehlmann; S Saussele; C Dietz; P Erben; A Fabarius; U Proetel; S Schnittger; S W Krause; J Schubert; H Einsele; M Hänel; J Dengler; C Falge; L Kanz; A Neubauer; M Kneba; F Stegelmann; M Pfreundschuh; C F Waller; K Spiekermann; G M Baerlocher; M Pfirrmann; J Hasford; W-K Hofmann; A Hochhaus; M C Müller
Journal:  Leukemia       Date:  2014-05-06       Impact factor: 11.528

5.  Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

Authors:  Elias Jabbour; Hagop M Kantarjian; Giuseppe Saglio; Juan Luis Steegmann; Neil P Shah; Concepción Boqué; Charles Chuah; Carolina Pavlovsky; Jirí Mayer; Jorge Cortes; Michele Baccarani; Dong-Wook Kim; M Brigid Bradley-Garelik; Hesham Mohamed; Mark Wildgust; Andreas Hochhaus
Journal:  Blood       Date:  2013-12-05       Impact factor: 22.113

6.  Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.

Authors:  David Marin; Corinne Hedgley; Richard E Clark; Jane Apperley; Letizia Foroni; Dragana Milojkovic; Christopher Pocock; John M Goldman; Stephen O'Brien
Journal:  Blood       Date:  2012-05-29       Impact factor: 22.113

7.  Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.

Authors:  Timothy P Hughes; Giuseppe Saglio; Hagop M Kantarjian; François Guilhot; Dietger Niederwieser; Gianantonio Rosti; Chiaki Nakaseko; Carmino Antonio De Souza; Matt E Kalaycio; Stephan Meier; Xiaolin Fan; Hans D Menssen; Richard A Larson; Andreas Hochhaus
Journal:  Blood       Date:  2013-12-11       Impact factor: 22.113

Review 8.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Authors:  Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann
Journal:  Blood       Date:  2013-06-26       Impact factor: 22.113

9.  Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.

Authors:  Preetesh Jain; Hagop Kantarjian; Aziz Nazha; Susan O'Brien; Elias Jabbour; Carlos Guillermo Romo; Sherry Pierce; Marylou Cardenas-Turanzas; Srdan Verstovsek; Gautam Borthakur; Farhad Ravandi; Alfonso Quintás-Cardama; Jorge Cortes
Journal:  Blood       Date:  2013-04-25       Impact factor: 22.113
  9 in total
  4 in total

Review 1.  Novel insights into the biology and treatment of chronic myeloproliferative neoplasms.

Authors:  Tariq I Mughal; Tiziano Barbui; Omar Abdel-Wahab; Robert Kralovics; Catriona Jamieson; Hans-Michael Kvasnicka; Ann Mullaly; Raajit Rampal; Ruben Mesa; Jean-Jacques Kiladjian; Michael Deininger; Josef Prchal; Rüdiger Hehlmann; Giuseppe Saglio; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2014-11-19

2.  The role of clinical pharmacists in treatment adherence: fast impact in suppression of chronic myeloid leukemia development and symptoms.

Authors:  Silmara Mendes Martins Moulin; Frederico Jacob Eutrópio; Jessica de Oliveira Souza; Fernanda de Oliveira Busato; David N Olivieri; Carlos Eduardo Tadokoro
Journal:  Support Care Cancer       Date:  2016-11-19       Impact factor: 3.603

Review 3.  Chronic myeloid leukemia: reminiscences and dreams.

Authors:  Tariq I Mughal; Jerald P Radich; Michael W Deininger; Jane F Apperley; Timothy P Hughes; Christine J Harrison; Carlo Gambacorti-Passerini; Giuseppe Saglio; Jorge Cortes; George Q Daley
Journal:  Haematologica       Date:  2016-05       Impact factor: 9.941

4.  A longitudinal evaluation of performance of automated BCR-ABL1 quantitation using cartridge-based detection system.

Authors:  Anoop Enjeti; Neil Granter; Asma Ashraf; Linda Fletcher; Susan Branford; Philip Rowlings; Susan Dooley
Journal:  Pathology       Date:  2015-10       Impact factor: 5.306
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.